Table of Content

1 Report Overview
1.1 Vaginosis Drug Definition
1.2 Market by Type
1.2.1 Global Vaginosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Rx
1.2.3 OTC
1.3 Market Segment by Application
1.3.1 Global Vaginosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Vaginosis Drug Sales
2.1 Global Vaginosis Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Vaginosis Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Vaginosis Drug Revenue by Region
2.3.1 Global Vaginosis Drug Revenue by Region (2018-2024)
2.3.2 Global Vaginosis Drug Revenue by Region (2024-2034)
2.4 Global Vaginosis Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Vaginosis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Vaginosis Drug Sales Quantity by Region
2.6.1 Global Vaginosis Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Vaginosis Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Vaginosis Drug Sales Quantity by Manufacturers
3.1.1 Global Vaginosis Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Vaginosis Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Vaginosis Drug Sales in 2022
3.2 Global Vaginosis Drug Revenue by Manufacturers
3.2.1 Global Vaginosis Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Vaginosis Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Vaginosis Drug Revenue in 2022
3.3 Global Vaginosis Drug Sales Price by Manufacturers
3.4 Global Key Players of Vaginosis Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Vaginosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Vaginosis Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Vaginosis Drug, Product Offered and Application
3.8 Global Key Manufacturers of Vaginosis Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Vaginosis Drug Sales Quantity by Type
4.1.1 Global Vaginosis Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Vaginosis Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Vaginosis Drug Revenue by Type
4.2.1 Global Vaginosis Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Vaginosis Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Vaginosis Drug Revenue Market Share by Type (2018-2034)
4.3 Global Vaginosis Drug Price by Type
4.3.1 Global Vaginosis Drug Price by Type (2018-2024)
4.3.2 Global Vaginosis Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Vaginosis Drug Sales Quantity by Application
5.1.1 Global Vaginosis Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Vaginosis Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Vaginosis Drug Revenue by Application
5.2.1 Global Vaginosis Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Vaginosis Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Vaginosis Drug Revenue Market Share by Application (2018-2034)
5.3 Global Vaginosis Drug Price by Application
5.3.1 Global Vaginosis Drug Price by Application (2018-2024)
5.3.2 Global Vaginosis Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Vaginosis Drug Sales by Company
6.1.1 North America Vaginosis Drug Revenue by Company (2018-2024)
6.1.2 North America Vaginosis Drug Sales Quantity by Company (2018-2024)
6.2 North America Vaginosis Drug Market Size by Type
6.2.1 North America Vaginosis Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Vaginosis Drug Revenue by Type (2018-2034)
6.3 North America Vaginosis Drug Market Size by Application
6.3.1 North America Vaginosis Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Vaginosis Drug Revenue by Application (2018-2034)
6.4 North America Vaginosis Drug Market Size by Country
6.4.1 North America Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Vaginosis Drug Revenue by Country (2018-2034)
6.4.3 North America Vaginosis Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Vaginosis Drug Sales by Company
7.1.1 Europe Vaginosis Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Vaginosis Drug Revenue by Company (2018-2024)
7.2 Europe Vaginosis Drug Market Size by Type
7.2.1 Europe Vaginosis Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Vaginosis Drug Revenue by Type (2018-2034)
7.3 Europe Vaginosis Drug Market Size by Application
7.3.1 Europe Vaginosis Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Vaginosis Drug Revenue by Application (2018-2034)
7.4 Europe Vaginosis Drug Market Size by Country
7.4.1 Europe Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Vaginosis Drug Revenue by Country (2018-2034)
7.4.3 Europe Vaginosis Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Vaginosis Drug Sales by Company
8.1.1 China Vaginosis Drug Sales Quantity by Company (2018-2024)
8.1.2 China Vaginosis Drug Revenue by Company (2018-2024)
8.2 China Vaginosis Drug Market Size by Type
8.2.1 China Vaginosis Drug Sales Quantity by Type (2018-2034)
8.2.2 China Vaginosis Drug Revenue by Type (2018-2034)
8.3 China Vaginosis Drug Market Size by Application
8.3.1 China Vaginosis Drug Sales Quantity by Application (2018-2034)
8.3.2 China Vaginosis Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Vaginosis Drug Sales by Company
9.1.1 APAC Vaginosis Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Vaginosis Drug Revenue by Company (2018-2024)
9.2 APAC Vaginosis Drug Market Size by Type
9.2.1 APAC Vaginosis Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Vaginosis Drug Revenue by Type (2018-2034)
9.3 APAC Vaginosis Drug Market Size by Application
9.3.1 APAC Vaginosis Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Vaginosis Drug Revenue by Application (2018-2034)
9.4 APAC Vaginosis Drug Market Size by Region
9.4.1 APAC Vaginosis Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Vaginosis Drug Revenue by Region (2018-2034)
9.4.3 APAC Vaginosis Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Vaginosis Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Vaginosis Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Vaginosis Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Vaginosis Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Bayer Vaginosis Drug Products and Services
11.1.5 Bayer Vaginosis Drug SWOT Analysis
11.1.6 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Pfizer Vaginosis Drug Products and Services
11.2.5 Pfizer Vaginosis Drug SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Sanofi Vaginosis Drug Products and Services
11.3.5 Sanofi Vaginosis Drug SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Piramal
11.4.1 Piramal Company Information
11.4.2 Piramal Overview
11.4.3 Piramal Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Piramal Vaginosis Drug Products and Services
11.4.5 Piramal Vaginosis Drug SWOT Analysis
11.4.6 Piramal Recent Developments
11.5 Abbott
11.5.1 Abbott Company Information
11.5.2 Abbott Overview
11.5.3 Abbott Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Abbott Vaginosis Drug Products and Services
11.5.5 Abbott Vaginosis Drug SWOT Analysis
11.5.6 Abbott Recent Developments
11.6 Galderma
11.6.1 Galderma Company Information
11.6.2 Galderma Overview
11.6.3 Galderma Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Galderma Vaginosis Drug Products and Services
11.6.5 Galderma Vaginosis Drug SWOT Analysis
11.6.6 Galderma Recent Developments
11.7 Mission
11.7.1 Mission Company Information
11.7.2 Mission Overview
11.7.3 Mission Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Mission Vaginosis Drug Products and Services
11.7.5 Mission Vaginosis Drug SWOT Analysis
11.7.6 Mission Recent Developments
11.8 Alkem
11.8.1 Alkem Company Information
11.8.2 Alkem Overview
11.8.3 Alkem Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Alkem Vaginosis Drug Products and Services
11.8.5 Alkem Vaginosis Drug SWOT Analysis
11.8.6 Alkem Recent Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Company Information
11.9.2 Xiuzheng Overview
11.9.3 Xiuzheng Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Xiuzheng Vaginosis Drug Products and Services
11.9.5 Xiuzheng Vaginosis Drug SWOT Analysis
11.9.6 Xiuzheng Recent Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Overview
11.10.3 Teva Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Teva Vaginosis Drug Products and Services
11.10.5 Teva Vaginosis Drug SWOT Analysis
11.10.6 Teva Recent Developments
11.11 Perrigo
11.11.1 Perrigo Company Information
11.11.2 Perrigo Overview
11.11.3 Perrigo Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Perrigo Vaginosis Drug Products and Services
11.11.5 Perrigo Recent Developments
11.12 West-Ward
11.12.1 West-Ward Company Information
11.12.2 West-Ward Overview
11.12.3 West-Ward Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 West-Ward Vaginosis Drug Products and Services
11.12.5 West-Ward Recent Developments
11.13 HPGC
11.13.1 HPGC Company Information
11.13.2 HPGC Overview
11.13.3 HPGC Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 HPGC Vaginosis Drug Products and Services
11.13.5 HPGC Recent Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Company Information
11.14.2 Yunnan Baiyao Overview
11.14.3 Yunnan Baiyao Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Yunnan Baiyao Vaginosis Drug Products and Services
11.14.5 Yunnan Baiyao Recent Developments
11.15 Starpharma
11.15.1 Starpharma Company Information
11.15.2 Starpharma Overview
11.15.3 Starpharma Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Starpharma Vaginosis Drug Products and Services
11.15.5 Starpharma Recent Developments
11.16 Novel
11.16.1 Novel Company Information
11.16.2 Novel Overview
11.16.3 Novel Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Novel Vaginosis Drug Products and Services
11.16.5 Novel Recent Developments
11.17 Edenvridge
11.17.1 Edenvridge Company Information
11.17.2 Edenvridge Overview
11.17.3 Edenvridge Vaginosis Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Edenvridge Vaginosis Drug Products and Services
11.17.5 Edenvridge Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Vaginosis Drug Value Chain Analysis
12.2 Vaginosis Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Vaginosis Drug Production Mode & Process
12.4 Vaginosis Drug Sales and Marketing
12.4.1 Vaginosis Drug Sales Channels
12.4.2 Vaginosis Drug Distributors
12.5 Vaginosis Drug Customers
13 Market Dynamics
13.1 Vaginosis Drug Industry Trends
13.2 Vaginosis Drug Market Drivers
13.3 Vaginosis Drug Market Challenges
13.4 Vaginosis Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Vaginosis Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Rx
Table 3. Major Manufacturers of OTC
Table 4. Global Vaginosis Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Vaginosis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Vaginosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Vaginosis Drug Revenue Market Share by Region (2018-2024)
Table 8. Global Vaginosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Vaginosis Drug Revenue Market Share by Region (2024-2034)
Table 10. Global Vaginosis Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 11. Global Vaginosis Drug Sales by Region (2018-2024) & (K Doses)
Table 12. Global Vaginosis Drug Sales Market Share by Region (2018-2024)
Table 13. Global Vaginosis Drug Sales by Region (2024-2034) & (K Doses)
Table 14. Global Vaginosis Drug Sales Market Share by Region (2024-2034)
Table 15. Global Vaginosis Drug Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 16. Global Vaginosis Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Vaginosis Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Vaginosis Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Vaginosis Drug Price by Manufacturers 2018-2024 (USD/Dose)
Table 20. Global Key Players of Vaginosis Drug, Industry Ranking, 2021 VS 2022
Table 21. Global Vaginosis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Vaginosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vaginosis Drug as of 2022)
Table 23. Global Key Manufacturers of Vaginosis Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Vaginosis Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Vaginosis Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 28. Global Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 29. Global Vaginosis Drug Sales Quantity Share by Type (2018-2024)
Table 30. Global Vaginosis Drug Sales Quantity Share by Type (2024-2034)
Table 31. Global Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Vaginosis Drug Revenue Share by Type (2018-2024)
Table 34. Global Vaginosis Drug Revenue Share by Type (2024-2034)
Table 35. Vaginosis Drug Price by Type (2018-2024) & (USD/Dose)
Table 36. Global Vaginosis Drug Price Forecast by Type (2024-2034) & (USD/Dose)
Table 37. Global Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 38. Global Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 39. Global Vaginosis Drug Sales Quantity Share by Application (2018-2024)
Table 40. Global Vaginosis Drug Sales Quantity Share by Application (2024-2034)
Table 41. Global Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Vaginosis Drug Revenue Share by Application (2018-2024)
Table 44. Global Vaginosis Drug Revenue Share by Application (2024-2034)
Table 45. Vaginosis Drug Price by Application (2018-2024) & (USD/Dose)
Table 46. Global Vaginosis Drug Price Forecast by Application (2024-2034) & (USD/Dose)
Table 47. North America Vaginosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Vaginosis Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 49. North America Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 50. North America Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 51. North America Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 54. North America Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 55. North America Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Vaginosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Vaginosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Vaginosis Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 61. North America Vaginosis Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 62. Europe Vaginosis Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 63. Europe Vaginosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 65. Europe Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 66. Europe Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 69. Europe Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 70. Europe Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Vaginosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Vaginosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Vaginosis Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 76. Europe Vaginosis Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 77. China Vaginosis Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 78. China Vaginosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 80. China Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 81. China Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 84. China Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 85. China Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Vaginosis Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 88. APAC Vaginosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 90. APAC Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 91. APAC Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 94. APAC Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 95. APAC Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Vaginosis Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Vaginosis Drug Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Vaginosis Drug Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Vaginosis Drug Sales Quantity by Region (2018-2024) & (K Doses)
Table 101. APAC Vaginosis Drug Sales Quantity by Region (2024-2034) & (K Doses)
Table 102. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Company (2018-2024) & (K Doses)
Table 103. Middle East, Africa and Latin America Vaginosis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Type (2018-2024) & (K Doses)
Table 105. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Type (2024-2034) & (K Doses)
Table 106. Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Vaginosis Drug Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Application (2018-2024) & (K Doses)
Table 109. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Application (2024-2034) & (K Doses)
Table 110. Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Vaginosis Drug Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Vaginosis Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Vaginosis Drug Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Country (2018-2024) & (K Doses)
Table 116. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity by Country (2024-2034) & (K Doses)
Table 117. Bayer Company Information
Table 118. Bayer Description and Overview
Table 119. Bayer Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 120. Bayer Vaginosis Drug Product and Services
Table 121. Bayer Vaginosis Drug SWOT Analysis
Table 122. Bayer Recent Developments
Table 123. Pfizer Company Information
Table 124. Pfizer Description and Overview
Table 125. Pfizer Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 126. Pfizer Vaginosis Drug Product and Services
Table 127. Pfizer Vaginosis Drug SWOT Analysis
Table 128. Pfizer Recent Developments
Table 129. Sanofi Company Information
Table 130. Sanofi Description and Overview
Table 131. Sanofi Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 132. Sanofi Vaginosis Drug Product and Services
Table 133. Sanofi Vaginosis Drug SWOT Analysis
Table 134. Sanofi Recent Developments
Table 135. Piramal Company Information
Table 136. Piramal Description and Overview
Table 137. Piramal Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 138. Piramal Vaginosis Drug Product and Services
Table 139. Piramal Vaginosis Drug SWOT Analysis
Table 140. Piramal Recent Developments
Table 141. Abbott Company Information
Table 142. Abbott Description and Overview
Table 143. Abbott Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 144. Abbott Vaginosis Drug Product and Services
Table 145. Abbott Vaginosis Drug SWOT Analysis
Table 146. Abbott Recent Developments
Table 147. Galderma Company Information
Table 148. Galderma Description and Overview
Table 149. Galderma Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 150. Galderma Vaginosis Drug Product and Services
Table 151. Galderma Vaginosis Drug SWOT Analysis
Table 152. Galderma Recent Developments
Table 153. Mission Company Information
Table 154. Mission Description and Overview
Table 155. Mission Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 156. Mission Vaginosis Drug Product and Services
Table 157. Mission Vaginosis Drug SWOT Analysis
Table 158. Mission Recent Developments
Table 159. Alkem Company Information
Table 160. Alkem Description and Overview
Table 161. Alkem Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 162. Alkem Vaginosis Drug Product and Services
Table 163. Alkem Vaginosis Drug SWOT Analysis
Table 164. Alkem Recent Developments
Table 165. Xiuzheng Company Information
Table 166. Xiuzheng Description and Overview
Table 167. Xiuzheng Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 168. Xiuzheng Vaginosis Drug Product and Services
Table 169. Xiuzheng Vaginosis Drug SWOT Analysis
Table 170. Xiuzheng Recent Developments
Table 171. Teva Company Information
Table 172. Teva Description and Overview
Table 173. Teva Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 174. Teva Vaginosis Drug Product and Services
Table 175. Teva Vaginosis Drug SWOT Analysis
Table 176. Teva Recent Developments
Table 177. Perrigo Company Information
Table 178. Perrigo Description and Overview
Table 179. Perrigo Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 180. Perrigo Vaginosis Drug Product and Services
Table 181. Perrigo Recent Developments
Table 182. West-Ward Company Information
Table 183. West-Ward Description and Overview
Table 184. West-Ward Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 185. West-Ward Vaginosis Drug Product and Services
Table 186. West-Ward Recent Developments
Table 187. HPGC Company Information
Table 188. HPGC Description and Overview
Table 189. HPGC Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 190. HPGC Vaginosis Drug Product and Services
Table 191. HPGC Recent Developments
Table 192. Yunnan Baiyao Company Information
Table 193. Yunnan Baiyao Description and Overview
Table 194. Yunnan Baiyao Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 195. Yunnan Baiyao Vaginosis Drug Product and Services
Table 196. Yunnan Baiyao Recent Developments
Table 197. Starpharma Company Information
Table 198. Starpharma Description and Overview
Table 199. Starpharma Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 200. Starpharma Vaginosis Drug Product and Services
Table 201. Starpharma Recent Developments
Table 202. Novel Company Information
Table 203. Novel Description and Overview
Table 204. Novel Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 205. Novel Vaginosis Drug Product and Services
Table 206. Novel Recent Developments
Table 207. Edenvridge Company Information
Table 208. Edenvridge Description and Overview
Table 209. Edenvridge Vaginosis Drug Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 210. Edenvridge Vaginosis Drug Product and Services
Table 211. Edenvridge Recent Developments
Table 212. Key Raw Materials Lists
Table 213. Raw Materials Key Suppliers Lists
Table 214. Vaginosis Drug Distributors List
Table 215. Vaginosis Drug Customers List
Table 216. Vaginosis Drug Market Trends
Table 217. Vaginosis Drug Market Drivers
Table 218. Vaginosis Drug Market Challenges
Table 219. Vaginosis Drug Market Restraints
Table 220. Research Programs/Design for This Report
Table 221. Key Data Information from Secondary Sources
Table 222. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaginosis Drug Product Picture
Figure 2. Global Vaginosis Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Vaginosis Drug Market Share by Type in 2022 & 2034
Figure 4. Rx Product Picture
Figure 5. OTC Product Picture
Figure 6. Global Vaginosis Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Vaginosis Drug Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Vaginosis Drug Report Years Considered
Figure 12. Global Vaginosis Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Vaginosis Drug Revenue 2018-2034 (US$ Million)
Figure 14. Global Vaginosis Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Vaginosis Drug Sales Quantity 2018-2034 (K Doses)
Figure 16. Global Vaginosis Drug Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Vaginosis Drug Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Vaginosis Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 19. North America Vaginosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Vaginosis Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. Europe Vaginosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Vaginosis Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. China Vaginosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Vaginosis Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. APAC Vaginosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. Middle East, Africa and Latin America Vaginosis Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Vaginosis Drug Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Vaginosis Drug Revenue in 2022
Figure 30. Vaginosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 33. Global Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 35. North America Vaginosis Drug Revenue Market Share by Company in 2022
Figure 36. North America Vaginosis Drug Sales Quantity Market Share by Company in 2022
Figure 37. North America Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 39. North America Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 41. North America Vaginosis Drug Revenue Share by Country (2018-2034)
Figure 42. North America Vaginosis Drug Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Vaginosis Drug Sales Quantity Market Share by Company in 2022
Figure 46. Europe Vaginosis Drug Revenue Market Share by Company in 2022
Figure 47. Europe Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 49. Europe Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 51. Europe Vaginosis Drug Revenue Share by Country (2018-2034)
Figure 52. Europe Vaginosis Drug Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 54. France Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 58. China Vaginosis Drug Sales Quantity Market Share by Company in 2022
Figure 59. China Vaginosis Drug Revenue Market Share by Company in 2022
Figure 60. China Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 62. China Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 64. APAC Vaginosis Drug Sales Quantity Market Share by Company in 2022
Figure 65. APAC Vaginosis Drug Revenue Market Share by Company in 2022
Figure 66. APAC Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 68. APAC Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 70. APAC Vaginosis Drug Revenue Share by Region (2018-2034)
Figure 71. APAC Vaginosis Drug Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 76. India Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Vaginosis Drug Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Vaginosis Drug Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Vaginosis Drug Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Vaginosis Drug Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Vaginosis Drug Revenue Share by Country (2018-2034)
Figure 85. Brazil Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Vaginosis Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Vaginosis Drug Value Chain
Figure 91. Vaginosis Drug Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed